Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vaxcyte, Inc.

34.28
-1.1100-3.14%
Post-market: 34.280.00000.00%16:05 EDT
Volume:1.59M
Turnover:54.89M
Market Cap:4.42B
PE:-9.01
High:35.56
Open:35.48
Low:34.17
Close:35.39
Loading ...

Vaxcyte Shares Drop 56% to Lowest Since October 2022 After Results From Vax-24 Infant Phase 2 Dose-Finding Study

THOMSON REUTERS
·
31 Mar

Vaxcyte VAX-24 Vaccine Data Missed Wall Street Expectations, But Fundamentally Still Positive, Mizuho Securities Says

MT Newswires Live
·
31 Mar

Wall Street Set to Open Lower Monday as Investors Gird for More Tariffs, Await Key Manufacturing Data

MT Newswires Live
·
31 Mar

Top Premarket Decliners

MT Newswires Live
·
31 Mar

Vaxcyte's Pneumococcal Conjugate Vaccine Candidate Shows Substantial Immune Response in Infants

MT Newswires Live
·
31 Mar

Investors Brace for 'Liberation Day' as US Futures Trend Sharply Lower in Monday's Premarket

MT Newswires Live
·
31 Mar

S&P 500 Futures Fall In Premarket Trading; Vaxcyte, Moderna Lag

Dow Jones
·
31 Mar

Vaxcyte reports topline results from VAX-24 infant Phase 2 dose-finding study

TIPRANKS
·
31 Mar

Vaxcyte Announces Positive Topline Results From Vax-24 Infant Phase 2 Dose-Finding Study

THOMSON REUTERS
·
31 Mar

Vaxcyte Inc - Vax-24 Well-Tolerated With Safety Profile Similar to Pcv20

THOMSON REUTERS
·
31 Mar

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

GlobeNewswire
·
31 Mar

Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?

Insider Monkey
·
27 Mar

Vaxcyte (PCVX) Struggled Amid Political Uncertainty

Insider Monkey
·
25 Mar

RFK's Op-Ed Should Give Biotech Hope -- Market Talk

Dow Jones
·
04 Mar

Vaxcyte’s Earnings Call Highlights Strong Position and Future Growth

TIPRANKS
·
28 Feb

Promising Outlook for Vaxcyte: Strong Execution and Financial Position Support Buy Rating

TIPRANKS
·
27 Feb

Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds

Insider Monkey
·
27 Feb

Stock Track | Vaxcyte Soars Over 5% as Positive Earnings and PCV Progress Boost Investor Sentiment

Stock Track
·
26 Feb

Vaxcyte Price Target Maintained With a $140.00/Share by Needham

Dow Jones
·
26 Feb

Q4 2024 Vaxcyte Inc Earnings Call

Thomson Reuters StreetEvents
·
26 Feb